Membership

The Working Group is a pathology-driven group of experts, assisted by experts clinicians, scientist and statisticians. The Working Group is open to open to include all pathologists willing to get involved in the activities of the group.

Please send an email to roberto@salgado.be

Information on Membership

    1. Membership of the Working Group is on a voluntary basis.
    2. All members will receive 2-3 times a year a mailing from the chair of the WG with the details of the ongoing projects so that all remain informed.
    3. This communication is done by e-mail and a copy of this mailing is posted on the BLOG of the TIL-website, under the item “Practical Info for all members”.
    4. In order to achieve uniformity in the methodology of scoring TILs worldwide, each member is encouraged to use the Internationally accepted guideline and do their part for promotion and dissemination of the guideline.

The following is a list of current members of the International Immuno-Oncology Working Group (TILs Working Group)*. A member is defined as a person willing to be involved, informed and be part of the activities of the TILs Working Group. The authors alone are responsible for the views expressed in the work of the TILs Working Group and they do not necessarily represent the decisions, policy or views of their employer.

  1. Roberto Salgado, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium (Co-Chair, Founder, Core-Group Member)
  2. Sherene Loi, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia (Co-Chair, Founder, Core-Group Member)
  3. Carsten Denkert, University of Marburg, Marburg, Germany (Co-Chair, Founder, Core-Group Member)
  4. Sunil Badve, Department of Pathology, Indiana University, Indianapolis, USA (Founder, Core-Group Member)
  5. Sandra Demaria, Department of Pathology, Weill-Cornell Medicine, New York, USA (Founder, Core-Group Member)
  6. Sylvia Adams, Perlmutter Cancer Center, New York University Medical School, New York, USA (Founder, Core-Group Member)
  7. Stefan Michiels, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France (Founder, Core-Group Member)
  8. David Rimm, Department of Pathology, Yale University School of Medicine, New Haven, USA (Core-Group Member)
  9. Fraser Symmans, Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, USA (Core-Group Member)
  10. Stephen Hewitt, Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA (Core-Group Member)
  11. John Bartlett, Ontario Institute for Cancer Research, Toronto, Canada; IGGM Edinburgh, UK (Core-Group Member)
  12. Torsten Nielsen, Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada (Core-Group Member)
  13. Christos Sotiriou, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium (Core-Group Member)
  14. Giuseppe Viale, Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy (Core-Group Member)
  15. Giancarlo Pruneri, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico–Isituto Nazionale dei Tumori, Universita degli Studi di Milano, Milan, Italy (Core-Group Member)
  16. Sybille Loibl, dlw Laborsoftware UG (haftungsbeschränkt) Lübben, Germany (Core-Group Member)
  17. Aini Hyytiäinen, Department of Oral and Maxillofacial Diseases, Helsinki, Finland
  18. Akira I. Hida, Department of Pathology, Matsuyama Shimin Hospital, Ehime, Japan
  19. Alastair Thompson, Surgical Oncology, Baylor College of Medicine, Texas, USA.
  20. Alex Lefevre, Roche Diagnostics, Belg
  21. Alexander J. Lazar, Departments of Pathology, Genomic Medicine, Dermatology, and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  22. Amy Lo, Research Pathology, Genentech Inc., South San Francisco, USA.
  23. Ana Sapino, University of Turin / Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Italy
  24. Anant Madabhushi, Case Western Reserve University; Louis Stokes Cleveland Veterans Health Administration Medical Center
  25. Andre Moreira, Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University, New York, New York, USA.
  26. Andrea Richardson, Department of Pathology, Johns Hopkins Hospital, Baltimore, USA.
  27. Andrea Vingiani, Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy.
  28. Andrew H. Beck, PathAI, Inc., Cambridge, USA
  29. Andrew Tutt, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
  30. Angel Guerrero, Department of Oncology, IVO Valencia, Spain.
  31. Anita Grigoriadis, Cancer Bioinformatics Lab, Cancer Centre at Guy’s Hospital, London, UK; School of Life Sciences and Medicine, King’s College London, London, UK
  32. Anna Ehinger, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Oncology and Pathology, Lund, Sweden
  33. Ana C. Garrido Castro, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  34. Anne Vincent-Salomon, Institut Curie, Paris Sciences Lettres Université, Inserm U934, Department of Pathology, Paris, France.
  35. Anne-Vibeke Laenkholm, Department of Surgical Pathology Zealand University Hospital, Demark
  36. Ashish Sharma, Department of Biomedical Informatics, Emory University, GA, USA
  37. Ashok Srinivasan, National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, Pennsylvania, USA.
  38. Balancin, Marcelo, Department of Pathology, University of São Paulo, São Paulo, Brazil.
  39. Balazs Acs, Department of Pathology, Karolinska Institute, Sweden
  40. Baljit Singh, Department of Pathology, New York University Langone Medical Centre, New York, USA.
  41. Bellizzi, Andrew M, Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, USA.
  42. Bellolio, Enrique, Department of Pathology, Universidad de La Frontera, Temuco, Chile.
  43. Benjamin Calhoun, Department of Pathology and Laboratory Medicine, UNC School of Medicine, USA.
  44. Benjamin Haibe-Kans, Bioinformatics and Computational Genomics Laboratory, Princess Margaret Cancer Center, Toronto, Canada.
  45. Benjamin Solomon, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  46. Bibhusal Thapa, Department of Medicine, University of Melbourne, Parkville, Australia.
  47. Blackley, Elizabeth F, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  48. Brad H. Nelson, Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada.
  49. Brandon Gallas, Division of Imaging, Diagnostics, and Software Reliability (DIDSR), Office of Science and Engineering Laboratories (OSEL), Center for Devices and Radiological Health (CDRH), Rockville, USA
  50. Broeckx, Glenn, Department of Pathology, University Hospital Antwerp, Belgium.
  51. Carlos Castaneda, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
  52. Carmen Ballesteroes-Merino, Providence Cancer Research Center, Portland, Oregon, USA.
  53. Carmen Criscitiello, Department of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy.
  54. Carolien Boeckx, Roche Diagnostics, Belgium.
  55. Carter, Jodi M, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA.
  56. Castaneda, Carlos, Department of Research, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú.
  57. Cecile Colpaert, Department of Pathology, AZ Turnhout, Turnhout, Belgium.
  58. Charles Swanton, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK
  59. Chennubhotla, Chakra S, Department of Computational and Systems Biology, University of Pittsburgh, USA.
  60. Cimino-Mathews, Ashley, Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA.
  61. Cinzia Solinas, Azienda AUSL, Regional Hospital of Aosta, Aosta, Italy..
  62. Cree, Ian, International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
  63. Crispin Hiley, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK
  64. Damien Drubay, Gustave Roussy, Universite Paris-Saclay, Villejuif, France; Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France
  65. Daniel Bethmann, University Hospital Halle (Saale), Institute of Pathology, Halle (Saale), Germany
  66. David A. Moore, Department of Pathology, UCL Cancer Institute, UCL, London, UK; University College Hospitals NHS Trust, London, UK.
  67. Deborah A. Dillon, Department of Pathology, Brigham and Women’s Hospital, Boston, MA Department of Pathology, Dana Farber Cancer Institute, Boston, MA
  68. Denis Larsimont, Department of Pathology, Jules Bordet Institute, Brussels, Belgium
  69. Dhanusha Sabanathan, Department of Clinical Medicine, Macquarie University, Sydney, Australia
  70. Doris Höflmayer, Institut für Pathologie , UK Hamburg, Germany.
  71. Douglas B. Johnson, Department of Medicine, Vanderbilt University Medical Centre, Nashville, USA.
  72. Aubrey Thompson, Department of Cancer Biology, Mayo Clinic, Jacksonville, USA.
  73. Edi Brogi, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  74. Edith Perez, Department of Oncology, Mayo Clinic, Rochester, USA.
  75. Ehab A. ElGabry, Roche, Tucson, USA
  76. El Bairi, Khalid, Cancer Biomarkers Working Group, Oujda, Morocco.
  77. Elisabeth Ida Specht Stovgaard, Department of Pathology, Herlev and Gentofte Hospital, Denmark
  78. Elvire Roblin, Université Paris-Saclay, Univ. Paris-Sud, Villejuif, France; and Service de biostatistique et d’épidémiologie, Gustave Roussy, Villejuif, France
  79. Ely, Scott, Translational Medicine, Bristol-Myers Squibb, Princeton, USA.
  80. Enrique Bellolio, Departamento de Anatomía Patológica, Universidad de La Frontera. Temuco – Chile
  81. Eva Balslev, Department of Pathology, Herlev and Gentofte Hospital, Denmark
  82. Ewa Chmielik, Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland.
  83. Fabien Gaire, Pathology and Tissue Analytics, Roche.
  84. Fabrice Andre, Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  85. Fang-I Lu, Sunnybrook Health Sciences Centre, Toronto, Canada
  86. Farid Azmoudeh-Ardalan, Tehran University of Medical Sciences, Iran.
  87. Federico Rojo, PathologyDepartment, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain
  88. Frahm, Isabel, Department of Pathology, Sanatorio Mater Dei, Buenos Aires, Argentina.
  89. Francesco Ciompi, Computational Pathology Group, Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands.
  90. Franklin Peale, Oncology Biomarker Development, Genentech-Roche.
  91. Fred R. Hirsch, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA.
  92. Frederick Klaushen, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany
  93. Frederique Penault-Llorca, Centre de Lutte Contre le cancer – Centre Jean Perrin, Clermont-Ferrand, France
  94. Gabriela Acosta-Haab, Department of Pathology, Hospital de Oncología Maria Curie, Buenos Aires, Argentina
  95. Gelareh Farshid, Directorate of Surgical Pathology, SA Pathology, Adelaide, Australia.
  96. Gert Van den Eynden, Department of Pathology, GZA-ZNA Ziekenhuizen, Wilrijk, Belgium.
  97. Giuseppe Curigliano, Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan, Italy
  98. Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, IRCCS; Milano
  99. Giuseppe Floris, KU Leuven- Univerisity of Leuven, Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and KU Leuven- University Hospitals Leuven, Department of Pathology, Leuven, Belgium
  100. Gluz, Oleg, Johanniter GmbH – Evangelisches Krankenhaus Bethesda Mönchengladbach, West German Study Group, Mönchengladbach, Germany.
  101. Goetz, Matthew P, Department of Oncology, Mayo Clinic, Rochester, USA.
  102. Gonzalez-Ericsson, Paula I, Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, USA.
  103. Gown, Allen, PhenoPath Laboratories, Seattle, USA.
  104. Harbeck, Nadia, Breast Center, Dept. OB&GYN and CCC (LMU), University of Munich, Munich, Germany.
  105. Harmut Koeppen, Research Pathology, Genentech Inc., South San Francisco, USA.
  106. Haynes, Harry R, Translational Health Sciences, Department of Cellular Pathology, North Bristol NHS Trust, University of Bristol UK
  107. Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland
  108. Helena Olofsson, Department of Clinical Pathology, Akademiska University Hospital, Uppsala, Sweden
  109. Hida, Akira I, Department of Pathology, Matsuyama Shimin Hospital, Matsuyama, Japan.
  110. Huang-Chun Lien, Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
  111. Hugo M. Horlings, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  112. I-Chun Chen, Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan),
  113. Iris Nederlof, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  114. Iva Brcic, Institute of Pathology, Medical University of Graz, Austria.
  115. Jack Chan, Department of Oncology, National Cancer Centre, Singapore.
  116. Jacqueline A. Hall, Vivactiv Ltd, Bellingdon, Bucks, UK.
  117. James Ziai, Research Pathology, Genentech Inc., South San Francisco, USA.
  118. Jan Hudeček, Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  119. Jane Brock, Department of Pathology, Brigham and Women’s Hospital, Boston, USA.
  120. Jelle Weseling, Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  121. Jennifer Giltnane, Research Pathology, Genentech Inc., South San Francisco, USA.
  122. Jennifer Kerner, PathAI Inc., Cambridge, USA
  123. Jeppe Thagaard, DTU Compute, Department of Applied Mathematics, Technical University of Denmark; Visiopharm A/S, Denmark
  124. Jeremy P. Braybrooke, Nuffield Department of Population Health, University of Oxford, Oxford and Department of Medical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
  125. Jeroen van der Laak, Computational Pathology Group, Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands
  126. Jerome Lemonnier, R&D UNICANCER, Paris, France
  127. Jiping Zha, Translational Sciences, MedImmune, Gaithersberg, USA.
  128. Joana Ribeiro, Breast Unit, Champalimaud Clinical Centre, Lisboa, Portugal
  129. Jochen K Lennerz, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
  130. Joël Cucherousset, GHI Le Raincy-Montfermeil, Chelles, Île-de-France, France
  131. Joel Saltz, Biomedical Informatics Department, Stony Brook University, Stony Brook, USA
  132. Johan Hartman, Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Solna, Sweden
  133. Johannes Hainfellner, Department of Medicine, Clinical Division of Oncology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria.
  134. Jonathon W. Juco, Merck & Co., Inc., Kenilworth, USA.
  135. Jorge Reis-Filho, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  136. Jose van den Berg, Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  137. Joselyn Sanchez, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  138. Joseph Sparano, Department of Medicine, Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein Medical Center, Bronx, USA.
  139. Juan Carlos Araya, Department of Pathology, Universidad de la Frontera, Temuco, Chile
  140. Julien Adam, Department of Pathology, Gustave Roussy, Grand Paris, France.
  141. Justin M. Balko, Departments of Medicine and Cancer Biology, Vanderbilt University Medical Centre, Nashville, USA.
  142. Kai Saeger, Vm Scope, Germany.
  143. Kalliopi (Popi) Siziopikou, Department of Pathology, Breast Pathology Section, Northwestern University, Chicago, USA
  144. Karen Willard-Gallo, Molecular Immunology Unit, Institut Jules Bordet, Brussels, Belgium.
  145. Karolina Sikorska, Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  146. Karsten Weber, German Breast Group, Neu-Isenburg, Germany.
  147. Katherine Pogue-Geile, NSABP/NRG Oncology, Pittsburgh, PA
  148. Keith E. Steele, Translational Sciences, MedImmune, Gaithersberg, USA.
  149. Kenneth Emancipator, Merck & Co., Inc., Kenilworth, USA.
  150. Khalid AbdulJabbar, Centre for Evolution and Cancer; Division of Molecular Pathology, The Institute of Cancer Research, London, UK
  151. Kim R.M. Blenman, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale School of Medicine, New Haven, CT , USA
  152. Kimberly H. Allison, Pathology Department, Stanford University Medical Centre, Stanford, USA.
  153. Koen K. van de Vijver, Department of Pathology, University Hospital Ghent, Belgium.
  154. Konstanty Korski, Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg, Germany
  155. Lajos Pusztai, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale School of Medicine, New Haven, CT , USA
  156. Laura Comerma, Pathology Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain
  157. Laurence Buisseret, Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  158. Lazar, Alexander, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA.
  159. Le Quesne, John, Leicester Cancer Research Centre, University of Leicester, Leicester, and MRC Toxicology Unit, University of Cambridge,
  160. Lee Cooper, Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL
  161. Leming Shi, Center for Pharmacogenomics and Fudan-Zhangjiang, Center for Clinical Genomics School of Life Sciences and Shanghai Cancer Center, Fudan University, China.
  162. Leon-Ferre, Roberto, Department of Oncology, Mayo Clinic, Rochester, USA.
  163. Leonie Voorwerk, Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  164. Lien, Huangchun, Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan.
  165. Loes FS Kooreman, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre and Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands
  166. Luciana Molinero, Oncology Biomarker Development, Genentech-Roche.
  167. Valeria Estrada, Biorepository and Tissue Technology Shared Resources, University of California San Diego, USA.
  168. Maartje Van Seijen, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  169. Magali Lacroix-Triki, Department of Pathology, Gustave Roussy, Villejuif, France.
  170. Maggie Cheang, Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, UK
  171. Maise al Bakir, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK
  172. Manu M Sebastian, Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  173. Marcelo L Balancin, Hospital das Clínicas, Sao Paulo, Brasil; Department of Pathology, Faculty of Medicine, University of São Paulo, Sao Paulo, Brasil
  174. Maria Vittoria Dieci, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.
  175. Marie-Christine Mathieu, Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France
  176. Mark van de Vijver, Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
  177. Marleen Kok, Divisions of Medical Oncology, Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  178. Marlon C. Rebelatto, Translational Sciences, MedImmune, Gaithersberg, USA.
  179. Martine Piccart, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
  180. Matthew G. Hanna, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  181. Matthias Preusser, Department of Medicine, Clinical Division of Oncology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria.
  182. McArthur, Heather, Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
  183. Mehrnoush Khojasteh, Roche Tissue Diagnostics, Digital Pathology, Santa Clara, CA, USA
  184. Melinda E. Sanders, Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Centre, Nashville, USA.
  185. Meredith M. Regan, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA
  186. Michael Barnes, Roche Diagnostics Information Solutions, Belmont, CA, USA
  187. Michael Christie, Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Australia.
  188. Michael Misialek, Vernon Cancer Center, Newton-Wellesley Hospital, Newton, USA.
  189. Michail Ignatiadis, Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  190. Michiel de Maaker, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  191. Mieke Van Bockstal, Service de pathologique, Cliniques universitaires Saint-Luc, Bruxelles, Belgique
  192. Miluska Castillo, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
  193. Mohamed Amgad, Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA
  194. Nadine Tung, Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, USA.
  195. Nele Laudus, University of Leuven, Belgium.
  196. Nicolas Sirtaine, Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  197. Nicole Burchardi, German Breast Group GmbH, Germany.
  198. Nils Ternes, Service de Biostatistique et d’Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.
  199. Nina Radosevic-Robin, Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France.
  200. Oliver Grimm, Pathology and Tissue Analytics, Roche.
  201. Paolo Nuciforo, Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain.
  202. Paul Jank, Department of Pathology, University of Marburg, Marburg, Germany.
  203. Paula Gonzalez-Ericsson, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
  204. Pawan Kirtani, Department of Histopathology, Manipal Hospitals Dwarka, New Delhi, India
  205. Peeters, Dieter, HistoGeneX NV, Antwerp, Belgium and AZ Sint-Maarten Hospital, Mechelen, Belgium.
  206. Peter H. Watson, Department of Pathology and Laboratory Medicine, University of British Columbia,
  207. Peter Jelinic, Merck & Co., Inc., Kenilworth, USA.
  208. Peter Savas, Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia; and The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
  209. Prudence A Francis, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
  210. Prudence A. Russell, Department of Anatomical Pathology, St Vincent’s Hospital Melbourne, Fitzroy, Australia.
  211. Quinn, Cecily, Department of Pathology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland
  212. Rajendra Singh, Icahn School of Medicine at Mt. Sinai, New York, NY, USA.
  213. Reisenbichler, Emily, Department of Pathology, Yale School of Medicine, New Haven, USA
  214. Robert H. Pierce, Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, USA.
  215. Robert Hills, Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, UK.
  216. Roland de Wind, Department of Pathology, Institut Jules Bordet, Brussels, Belgium.
  217. Ruohong Shui, Department of Pathology, Fudan University Cancer Center, China.
  218. Sabine Declercq, Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium
  219. Sam Leung, University of British Columbia, Vancouver, British Columbia, Canada.
  220. Sami Tabbarah​, Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Research Institute, Toronto, Canada
  221. Sandra C Souza, Oncology Merck & Co, New Jersey, USA
  222. Sandra O’Toole, The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Australian Clinical Labs, Australia.
  223. Sandra Swain, Georgetown University Medical Center, Washington DC, USA.
  224. Sarah Dudgeon, FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, USA
  225. Scooter Willis, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD, USA.
  226. Seong- Rim Kim, National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, USA
  227. Shahinaz Bedri, Anatomic Pathology, Boston, Massachusetts, USA.
  228. Sheeba Irshad, Guy’s Hospital, London, UK; King’s College London, London, UK
  229. Shi-Wei Liu, Peking University First Hospital Breast Disease Center, Beijing, China.
  230. Shi-wei, Liu, Sichuan Cancer Hospital, Chengdu, China.
  231. Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
  232. Shona Hendry, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  233. Simonetta Bianchi, Dipartimento di Scienze della Salute (DSS), Firenze, Italy.
  234. Sofia Bragança, Department of Oncology, Champalimaud Clinical Centre, Lisbon, Portugal.
  235. Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, Pennsylvania, USA.
  236. Stephan Wienert, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany
  237. Stephen B. Fox, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  239. Stephen J. Luen, Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
  240. Stephen Naber, Department of Pathology and Laboratory Medicine, Tufts Medical Center
  241. Stuart Schnitt, Department of Pathology, Brigham and Women’s Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA, USA.
  242. Sua Luz, Department of Pathology, Fundación Valle del Lili, Cali, Colombia.
  243. Sunil R. Lakhani, The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia
  244. Susan Fineberg, Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, United States
  245. Teresa Soler, Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, L’Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain
  246. Thomas Gevaert, Department of Development and Regeneration, Laboratory of Experimental Urology, KU Leuven, Leuven, Belgium.
  247. Timothy d’Alfons, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  248. Tina Gruosso, Forbius, Translational Research, Montreal, Canada.
  249. Tom John, Department of Medical Oncology, Austin Health, Heidelberg, Australia.
  250. Tomohagu Sugie, Department of Surgery, Kansai Medical School, Hirakata, Japan.
  251. Uday Kurkure, Roche Tissue Diagnostics, Digital Pathology, Santa Clara, CA, USA.
  252. Veerle Bossuyt, Department of Pathology, Massachusetts General Hospital, USA.
  253. Venkata Manem, Bioinformatics and Computational Genomics Laboratory, Princess Margaret Cancer Center, Toronto, Canada.
  254. Vincente Peg Cámaea, Pathology Department, H.U. Vall d’Hebron, Barcelona, Spain.
  255. Weida Tong, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, USA.
  256. Weijie Chen, Division of Imaging, Diagnostics, and Software Reliability (DIDSR), Office of Science and Engineering Laboratories (OSEL), Center for Devices and Radiological Health (CDRH), Rockville, USA
  257. Wentao Yang, Department of Pathology, Fudan University Cancer Center, China.
  258. William T. Tran, Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Research Institute, Toronto, Canada
  259. Yihong Wang, Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Providence, USA.
  260. Yinyin Yuan, Centre for Evolution and Cancer; Division of Molecular Pathology, The Institute of Cancer Research, London, UK
  261. Yves Allory, Université Paris-Est, Créteil, France.
  262. Zaheed Husain, Praava Health, Dhaka, Bangladesh
  263. Zardavas, Dimitrios, Oncology Clinical Development, Bristol-Myers Squibb, Princeton, USA.
  264. Zsuzsanna Bago-Horvath, Department of Pathology, Medical University of Vienna, Vienna, Austria
  265. Zuzana Kos, Department of Pathology, BC Cancer Agency Vancouver Centre, Department of Pathology, Canada
*Update in progress. Please email roberto@salgado.be for any changes.